The expression of Epstein-Barr virus (EBV)-determined antigens associated with growth-transformation of B cells was studied by immunoblotting with human sera from healthy donors. Four antigens were detected in EBV-carrying cell lines and in B lymphocytes early after infection with the transforming B95-8 substrain of virus. They were not found in uninfected cells, nor could they be demonstrated with sera lacking antibodies to EBV antigens. AU four antigens were nuclear. Each of them varied in size in the different cell lines. The two antigens with the lowest molecular weight were identified as EBV-determined nuclear antigens (EBNAs) 1 and 2. The two high molecular weight antigens (140-160 kDa and 150-180 kDa, respectively) were detected with 6 of 16 EBV antibody-positive sera. These proteins appeared to be antigenically unrelated to each other and to EBNAs 1 and 2 and were designated EBNAs 3 and 4. Like EBNAs 1 and 2, they bound to double-and single-stranded DNA in vitro.
EBV-transformed lymphoblastoid cell lines (LCLs) designated SPIM-xxx were established by spontaneous outgrowth from peripheral blood of patients with IM. Virus production in B95-8 cells was induced as described (14) . At the time of harvest (24 hr), the culture contained 26% early antigen (EA)-positive cells and 19% viral capsid antigen (VCA)-positive cells.
Subcellular Fractionation, DNA Cellulose Chromatography, and Immunoblotting. Washed cells were lysed in Nonidet P-40 (NP-40) buffer as described (11) . The nuclear pellet was washed once with the same buffer without NP-40, and the nuclei were collected by centrifugation. The nuclear wash and the NP-40 supernate were combined and designated cytoplasm (see Fig. 4 ). The nuclear pellet was sequentially washed with 0.15, 0.40, and 2.0 M NaCl (in 20 mM Tris-HCl, pH 7.5/2 mM MgCl2). The resulting pellet was suspended in electrophoresis sample buffer.
Chromatography on single-stranded (ss) and double-stranded (ds) DNA-cellulose was as described (14) . Briefly, the 0.4 M NaCl extract from 2 x 108 IB4 cells was diluted to 150 mM NaCl, and EDTA was added to a final concentration of 5 mM. The nuclear extract was loaded onto columns (2 ml) of ss or ds DNA-cellulose. Bound proteins were eluted stepwise with 5 ml of 0.25, 0.35, and 0.60 M NaCl. Electrophoresis and immunoblotting were performed with gels containing 9% acrylamide and 0.1% N,N'-methylenebisacrylamide or with 7.5% acrylamide and 0.2% N,N'-methylenebisacrylamide as described (9, 11) .
RESULTS
Screening of Human Sera by Immunoblotting. Blots of Raji and Ramos cells were incubated with the sera listed in Table  1 . Seven of these sera were from donors lacking antibodies to EBV and 16 were from healthy seropositive donors. The serum WC is derived from a patient with chronic IM (15) . Fifteen of the EBV-positive sera reacted with a 69-kDa protein of Raji cells that was identified as EBNA 1 with specific anti-peptide antisera (9) (Table 1) . Eleven sera reacted with a 103-kDa polypeptide of the Raji extract that was classified as EBNA 2 on the basis of its reactivity with antibodies to synthetic peptides deduced from the nucleotide sequence of the BamHI YH region (11) . Seven of the EBNA 2 antibody-positive sera reacted with an additional 143-kDa polypeptide of the Raji extract. Six of these sera also reacted with a 180-kDa Raji polypeptide. These two high molecular weight polypeptides are hereafter referred to as EBNA 3 and EBNA 4, respectively. Fig. 1 shows blots with two EBVAbbreviations: kb, kilobases; EBV, Epstein-Barr virus; EBNA, EBV-determined nuclear antigen; LCL, lymphoblastoid cell line; BL, Burkitt lymphoma; ss, single-stranded; ds, double-stranded; IM, infectious mononucleosis; ACIF, anti-complement immunofluorescence; EA, early antigen; VCA, viral capsid antigen.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (Fig. 3) . With three exceptions (Salim Mwalim, Raji, and Namalwa), expression of EBNA 3 and EBNA 4 was generally lower than in the LCLs. P3HR-1 and Jijoye cells had a similar size distribution of EBNAs 3 and 4 as observed in Namalwa and IB4 cells (Fig. 3) . The apparent molecular weights obtained by electrophoresis on gels with low crosslinking (Figs. 1, 2, and 3A ) was compared to that obtained with gels of normal crosslinking (Table 3 gels with low crosslinking was 180 kDa, whereas gels with normal crosslinking yielded a value of 160 kDa. Similarly, the molecular weight determination for EBNA 3 varied proportionally depending on the gel system used ( Table 3 ). The migration of EBNA 2 was significantly slower on gels with low crosslinking than on gels with normal crosslinking. This is clearly depicted with EBNA 1 and EBNA 2 of M139 cells where the two antigens migrate in a well-separated manner (Fig. 3A) but comigrate on gels with normal crosslinking (Fig.  3B ). The EBNA 2 band was composed of three molecular species differing slightly with respect to their mobility (Fig.   3B ).
Expression of EBNA-Associated Antigens in Human B Lymphocytes Infected with B95-8 Virus. In infected B cells, EBNA 2 and trace amounts of EBNAs 1 and 3 were detected on day 1 (Fig. 4) . On day 2 the expression of EBNAs 1, 2, and 3 had increased to levels comparable to those of IB4 cells. On day 3, EBNA 4 appeared as two polypeptides (166 and 180 kDa) as in B95-8 cells (Fig. 2A) . The pattern ofexpression did not change qualitatively from day 3 on and was almost the same as that of the B95-8-transformed cells (Fig. 2B) .
Subcellular Localization of the Four EBNA-Related Polypeptides. IB4 cells were fractionated into cytoplasm and nuclei. The nuclei were washed sequentially with increasing concentrations of NaCl. EBNAs 1, 2, and 3 were readily detected in whole-cell extracts, whereas EBNA 4 appeared only as a faint band (Fig. 5) . In the nuclear fraction, EBNAs 2, 3, and 4 were enriched, whereas very little ofthese antigens was found in the cytoplasm. EBNA 1 was detected both in nuclei and in the cytoplasm. Sequential extraction of nuclear proteins with 0.15, 0.4, and 2 M NaCl revealed that 0.4 M NaCl was sufficient to solubilize most of EBNAs 2, 3, and 4; only trace amounts were found in the 2 M extract. After extraction with 2 M NaCl, EBNAs 2, 3, and 4 were readily detected in the pellet. EBNA 1 was detected in the 0.4 and 2.0 M NaCl extracts as well as in the residual pellet. The biphasic extraction profile of EBNAs 2, 3, and 4 was reproduced with Raji cells (not shown).
DNA-Cellulose Chromatography. In vitro binding to DNA was performed in 0.15 M NaCl, and bound proteins were eluted by stepwise increase of the NaCl concentration of the eluent. With ss DNA-cellulose (Fig. 6A) , most of EBNA 3 was detected in the 0.25 M NaCl eluate. Trace amounts of EBNA 3 were found in the column flow-through. EBNA 1 and EBNA 2 were detected preferentially in the 0.35 M and 0.6 M ss DNA eluates, whereas EBNA 4 was detected in the 0.35 M NaCl eluate. The low molecular weight species of EBNA 2 were eluted preferentially with 0.25 M NaCl, whereas the major (and largest) component was dominant in the 0.6 M NaCl eluate. With ds DNA, the elution profile was similar but not identical (Fig. 6B) . Most of EBNA 3 and small amounts of EBNA 1 failed to bind to ds DNA. The relative order of elution, EBNA 3, EBNA 4, EBNA 2, and EBNA 1, was the same as with ss DNA. 
DISCUSSION
The following criteria were applied for the identification of EBNAs in cell extracts: (i) the antigen should be detected only with EBV-positive sera; (ii) it should only be expressed in EBV-carrying cells; (iii) it should be detectable in all lymphoblastoid cell lines that depend on EBV for their proliferation; and (iv) it should be expressed in B lymphocytes after infection with transforming EBV.
The first three criteria have been met for EBNAs 1 and 2 (5). Later it was shown that these two proteins are encoded by the virus (8, 9, 11, 12) . Now we show that all four criteria are met by EBNAs 3 and 4 and, as expected, also by EBNAs 1 and 2. We found also that the size of EBNAs 3 and 4 is determined by the infecting virus. The molecular species of In the primary infection, EBNA 2 appears slightly before EBNAs 1, 3, and 4. This finding is in line with the suggestion that the EBNA 2-coding region of the viral genome is involved with early activation-events leading to immortalization of B cells (2) . EBNAs 1, 3, and 4 followed a similar pattern of appearance. Starting on day 3 of the primary infection, all four EBNA antigens were expressed to similar levels as in the virustransformed cell lines.
BL-derived cell lines express less EBNA 3 and EBNA 4 than did the LCLs, as a rule. Also, many of the BL-derived lines contained no detectable EBNA 2. It is conceivable that EBNA 2 is not required for the proliferation of the malignant, tumorigenic BL cells or for the maintenance of the viral genomes. EBNAs 3 and 4 are compartmentalized in the cell and solubilized in a fashion nearly indistinguishable from EBNA 2 (11). Moreover, EBNAs 3 and 4 bind, like EBNAs 1 and 2, to ss and ds DNA in vitro. The conditions for binding were the same as were used for the purification of the viral DNA polymerase and the viral alkaline nuclease (14) . Therefore, it is likely that EBNAs 3 and 4 also interact with DNA in vivo as suggested for EBNA 1 (16) .
Several lines of evidence suggest that EBNAs 3 and 4 are neither interrelated nor related to EBNAs 1 and 2. First, there was no covariation in apparent molecular weight between the four antigens. EBNAs 3 and 4 were expressed in cell lines with deleted EBNA 2-coding sequences (P3HR-1, Daudi, and Naliaka). Second, sera raised against the Ala-Gly repeat of EBNA 1 (9) and against two domains of EBNA 2 (11) did not react with EBNA 3 or EBNA 4. Two sera (Table 1) reacted well with EBNA 3 but not at all with EBNA 4. Therefore, it is unlikely that EBNA 3 and EBNA 4 share antigenic determinants. Most of the experiments used gels with lower crosslinking than previously used (4, 9, 11). On this type of gel, the apparent molecular weights for EBNAs 3 and 4 varied between 140 and 157 kDa and between 150 and 190 kDa, respectively. On gels with normal crosslinking, the apparent molecular weights were about 10% lower (136-143 kDa for EBNA 3 and 150-160 kDa for EBNA 4). Although EBNAs 3 and 4 migrate close to major EA and late antigens (14) , these antigens were not detected on immunoblots with the KF serum and extracts of virus-producing B95-8 cells (Fig. 2A) . Since we observed no changes in the levels of EBNA 3 and EBNA 4 expression in cells ranging from <0.01% EA (Raji and IB4) to more than 20% EA (induced B95-8), we conclude that neither of these two antigens is related to the productive viral cycle. They are clearly associated with the latent infection of immortalized cells.
The size-variation of EBNA 4 seems to differ from that of EBNAs 1, 2, and 3. Under conditions where EBNAs 1, 2, and 3 migrated as single bands, EBNA 4 often appeared as two bands. This was well illustrated in B95-8 cells and in LCLs transformed by B95-8 virus, where EBNA 4 migrated as two bands of 166 and 180 kDa. It is possible that EBNA 4 undergoes posttranslational processing or that the mRNA for EBNA 4 has two alternative splicing patterns.
Recently, Sculley et al. (17) described multiple nuclear antigens in EBV-infected cells. Two of these antigens were assigned molecular weights of 110 and 115 kDa, respectively. Using a reference serum supplied by Sculley, we detected EBNAs 3 and 4 with blots of Raji and IB4 cells. The discrepancy in molecular weights could be due to the fact that Sculley et al. used no molecular weight markers larger than 92 kDa. The EBNA 3 and EBNA 4 herein reported are not accounted for by available transcription data (2). Sculley et al. (17) suggested that their high molecular weight nuclear antigens were associated with the putative transforming region of the viral genome. As we could detect EBNAs 3 and 4 in cell lines with deletions in the putative transforming sequences (18), we suggest that EBNAs 3 and 4 are encoded by sequences outside the previously known transcribed areas of the viral genome.
